What Do Analysts Think About Gilead Sciences (GILD)?

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best large cap value stocks to buy now. On September 22, Morgan Stanley analyst Terence Flynn maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD), keeping the associated price target the same at $143.00.

Why Gilead Sciences (GILD) Deserves Attention in the Cheap Quarterly Dividend Stocks Category

The analyst based the optimistic rating on Gilead Sciences, Inc.’s (NASDAQ:GILD) positive outlook and potential growth, reasoning that a notable endorsement is the recent update from the US CDC recommending the company’s Yeztugo for HIV pre-exposure prophylaxis (PrEP).

Similarly, JPMorgan analyst Chris Schott raised the firm’s price target on Gilead Sciences, Inc. (NASDAQ:GILD) to $145 from $135 on September 16, keeping an Overweight rating on the shares.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biotech company that advances medicines to prevent and treat serious diseases such as cancer, immunodeficiency virus (HIV), viral hepatitis, and COVID-19.

Its portfolio of drugs focuses on medical areas with unmet needs and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others. Gilead Sciences, Inc. (NASDAQ:GILD) operates in over 35 countries.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.